TY - JOUR
T1 - Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients
T2 - A retrospective case-matched study
AU - Morabito, Fortunato
AU - Bringhen, Sara
AU - Larocca, Alessandra
AU - Wijermans, Pierre
AU - Victoria Mateos, Maria
AU - Gimsing, Peter
AU - Mazzone, Carla
AU - Gottardi, Daniela
AU - Omedè, Paola
AU - Zweegman, Sonja
AU - José Lahuerta, Juan
AU - Zambello, Renato
AU - Musto, Pellegrino
AU - Magarotto, Valeria
AU - Schaafsma, Martijn
AU - Oriol, Albert
AU - Juliusson, Gunnar
AU - Cerrato, Chiara
AU - Catalano, Lucio
AU - Gentile, Massimo
AU - Isabel Turel, Ana
AU - Marina Liberati, Anna
AU - Cavalli, Maide
AU - Rossi, Davide
AU - Passera, Roberto
AU - Rosso, Stefano
AU - Beksac, Meral
AU - Cavo, Michele
AU - Waage, Anders
AU - San Miguel, Jesus
AU - Boccadoro, Mario
AU - Sonneveld, Pieter
AU - Palumbo, Antonio
AU - Offidani, Massimo
PY - 2014
Y1 - 2014
N2 - Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P
AB - Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P
UR - http://www.scopus.com/inward/record.url?scp=84897388164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897388164&partnerID=8YFLogxK
U2 - 10.1002/ajh.23641
DO - 10.1002/ajh.23641
M3 - Article
C2 - 24273190
AN - SCOPUS:84897388164
SN - 0361-8609
VL - 89
SP - 355
EP - 362
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 4
ER -